Safety and effectiveness of umbilical vein oxytocics injection in hypertensive and cardiac parturient

ABSTRACT

Systemic injection of ergometrine and oxytocics for hypertensive and cardiac patients constitutes a real risk. 100 patients were included in this study, all were hypertensive except 5 cardiac patients. Different oxytocics were injected in the umbilical vein in the 3rd stage of labor in 55 hypertensive and 5 cardiac patients compared with distilled water in 20 parturient and another 20 patients received nothing. Those who received intraumbilical [IU] vein prostaglandin E2 had significantly shorter mean placental separation time followed by oxytocin and lastly ergometrine and distilled water. There is a decreased incidence of postpartum hemorrhage and retension of the placenta and increase in the mean hemoglobin on the second postpartum day. There is no significant difference of the mean arterial blood pressure and pulse rate before and after injection of umbilical vein by these oxytocics. Oxytocin and ergometrine IU vein injection appeared to be safer and effective compared to prostaglandin E2 and nothing. So, IU vein injection of oxytocin and ergometrine is recommended in hypertensive and cardiac patients as a preventive approach for postpartum hemorrhage in those high risk group rather than systemic injection